Table 3.
Performance of Texas HCC Risk Index in the Texas Hepatocellular Carcinoma Consortium (THCCC) and the Houston Veterans Administration Cirrhosis Surveillance Cohorts (HVASC) [Derivation Cohort] and the Veterans Health Administration Cirrhosis Cohort [Validation Cohort].
| Timeframe | No. at the end of the year in the harmonized THCCC and HVASC cohorts | AUROC in THCCC and HVASC cohorts after internal validation (95% CI) | No. at the end of the year in the VA cirrhosis cohort | AUROC in VA cirrhosis cohort (95% CI) |
|---|---|---|---|---|
| 1 year | 2271 | 0.78 (0.71, 0.85) |
19617 | 0.70 (0.67–0.74) |
| 2 years | 1927 | 0.78 (0.73, 0.83) |
14760 | 0.70 (0.68–0.73) |
| 3 years | 1293 | 0.75 (0.70, 0.80) |
NR | NR |
The AUC at 3 years is not reported for the external validation because the time period of observation was not long enough to obtain reliable estimates at 3 years